يحاول ذهب - حر
Can DPDPA's Research Exemption Power Private Sector Breakthroughs?
October 2025
|Bio Spectrum
India's Digital Personal Data Protection Act, 2023 (DPDPA), imposes uniform data protection obligations across sectors, significantly affecting healthcare, pharma, and biotech firms due to their use of sensitive personal data. Section 17(2) (b) provides limited exemptions for "research, archiving, or statistical purposes," which some stakeholders interpret as broad immunity.
-
This article challenges that view, arguing that Indian policy generally restricts exemptions for private, profit-driven research unless a clear public interest is demonstrated. Drawing on parallels with the GDPR, it concludes that the exemption will likely be narrowly construed, and the forthcoming DPDPA Rules are unlikely to support a wide carve-out.
The Digital Personal Data Protection Act, 2023 (DPDPA) is a law that primarily affects and benefits people and organisations that deal with personal data.
From tech giants to hospitals, from law firms to educational boards, the law places clear obligations on all those processing personal data. Healthcare, pharma, and biotech companies are no exception. While much attention has been drawn to how social media companies are affected, the impact on healthcare, pharma, and biotech sectors has not been adequately analysed.
Many such companies believe that the research exemption under Section 17(2)(b) of the DPDPA will save them from onerous compliance. But that belief may be flawed. In this article, we explain why.
The regulatory intent behind Sec. 17(2)(b) of DPDPA
Section 17(2)(b) allows personal data use for research, archiving, or statistics, if not tied to individuals and done per government norms.
It reads as:
- ‘(b) necessary for research, archiving or statistical purposes if the personal data is not to be used to take any decision specific to a Data Principal and such processing is carried on in accordance with such standards as may be prescribed.’
The “standards as may be prescribed” have not yet been prescribed, which means the exemption is not yet live. The rules for the DPDPA will propose standards and give other clarifications regarding the clause.
The direction of India’s public policy
هذه القصة من طبعة October 2025 من Bio Spectrum.
اشترك في Magzter GOLD للوصول إلى آلاف القصص المتميزة المنسقة، وأكثر من 9000 مجلة وصحيفة.
هل أنت مشترك بالفعل؟ تسجيل الدخول
المزيد من القصص من Bio Spectrum
Bio Spectrum
Building Breakthrough Medical Devices
Dr Ria Khurana founded RNT Health Insights, a Chandigarh-based healthtech startup specialising in Al-assisted diagnostic solutions for the accurate detection of pathologies during endoscopic procedures, in 2022 along with Dr Tanmaya Gulati.
2 mins
January 2026
Bio Spectrum
Bridging classical epidemiology with modern science
A physician scientist with a MBBS from Lady Hardinge Medical College, (University of Delhi), a post-graduation in Paediatrics and a PhD from All India Institute of Medical Sciences (AIIMS), New Delhi, Prof.Shinjini Bhatnagar served as Professor of Eminence at Translational Health Science and Technology Institute (THSTI) until February 2023 and was subsequently appointed Distinguished Professor at THSTI until May 2025.
2 mins
January 2026
Bio Spectrum
"AI, Automation & Analytics: A new era of modern microbiology testing!"
Pharmaceutical manufacturing is undergoing a paradigm shift.
4 mins
January 2026
Bio Spectrum
The CRISPR Moment
CRISPR (clustered regularly interspaced short palindromic repeats) technology is ushering in a new era of gene and cell therapy, offering more precision and potential for treating genetic disorders, cancer, and infectious diseases.
2 mins
January 2026
Bio Spectrum
Leveraging Microfluidic Technology for mRNA-LNP Manufacturing
Over the past five years, messenger RNA (mRNA) therapeutics have evolved from experimental concepts into lifesaving medicines.
2 mins
January 2026
Bio Spectrum
Demonstrating India's Vaccine Capabilities
Havisure is India's first and only indigenously developed Hepatitis A vaccine, to address one of the country's most persistent public health challengeswidespread Hepatitis A infections caused by inadequate sanitation and contaminated food and water.
2 mins
January 2026
Bio Spectrum
Inspiring Future Generations
A PhD in molecular biology from the University of Cambridge, UK, Prof. Gaiti Hasan is a Distinguished Fellow at the National Centre for Biological Sciences (NCBS), Bengaluru.
2 mins
January 2026
Bio Spectrum
A Landmark for India's Antibiotic Innovation
After three decades of research and hard work, India has led the way with the creation of Nafithromycin, the country's first indigenous antibiotic.
2 mins
January 2026
Bio Spectrum
"Future vaccine innovation will be integration of R&D, regulatory support and manufacturing”
TechInvention Lifecare Limited, a vaccine focused biotechnology company headquartered in Mumbai, is recognised for its innovative contributions to global healthcare.
4 mins
January 2026
Bio Spectrum
Telangana: Building India's Most Credible Life Sciences Ecosystem
Telangana's recognition as BioSpectrum India's Best Performing State in Life Sciences 2025 is a timely validation of the direction the state has taken in recent years-one anchored in execution, responsiveness, and a clear understanding of where global life sciences value chains are headed.
4 mins
January 2026
Listen
Translate
Change font size

